Meeting
2023 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
Authors
Jessica Jiyeong Lin
Department of Medicine, Massachusetts General Hospital, Boston, MA
Jessica Jiyeong Lin , Daniel Shao-Weng Tan , Shivaani Kummar , Jyoti D. Patel , Luciano Cermignani , Ming-Shen Dai , Ulrik Niels Lassen , Serge Leyvraz , Yongmei Liu , Victor Moreno , Lee S. Rosen , Esma Saada-Bouzid , Benjamin Maurice Solomon , Rui-Hua Xu , Jeffrey Yachnin , Ricarda Norenberg , Domnita-Ileana Burcoveanu , Chiara E. Mussi , Lin Shen , Alexander E. Drilon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02576431 and NCT02122913
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9056)
DOI
10.1200/JCO.2023.41.16_suppl.9056
Abstract #
9056
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
First Author: Alexander E. Drilon
Poster
2024 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.
First Author: Alexander E. Drilon
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong
Poster
2023 ASCO Annual Meeting
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
First Author: Maria E. Cabanillas